Investigating how a chickenpox vaccine can be improved to reduce complications.
VZV vaccine attenuation and the DNA damage response
This study is looking at how to make the chickenpox vaccine better by understanding the virus's genetics, so it can help protect adults from getting shingles and its complications with fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10868726 on NIH RePORTER |
What this research studies
This research focuses on enhancing the live attenuated vaccine for Varicella Zoster Virus (VZV), which causes chickenpox and can lead to debilitating conditions like Herpes Zoster (shingles). The study aims to understand the genetic factors that contribute to the vaccine's effectiveness and safety, particularly looking at specific genetic variations in the virus. By analyzing how these variations affect the vaccine's ability to prevent disease, the research seeks to develop a more effective vaccine that minimizes side effects and improves immunity in adults. Patients may benefit from improved vaccination strategies that reduce the risk of shingles and its complications.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults who have not been vaccinated against chickenpox or those at risk of developing shingles.
Not a fit: Patients who have already received the current chickenpox vaccine or those with a history of severe allergic reactions to vaccines may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective chickenpox vaccine that significantly reduces the incidence of shingles and its associated chronic pain.
How similar studies have performed: Previous research has shown promise in improving vaccine efficacy through genetic modifications, indicating that this approach may yield beneficial results.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Kinchington, Paul R. — University of Pittsburgh at Pittsburgh
- Study coordinator: Kinchington, Paul R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.